Asset Details
Do you wish to reserve the book?
Ocular RNA nanomedicine: engineered delivery nanoplatforms in treating eye diseases
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ocular RNA nanomedicine: engineered delivery nanoplatforms in treating eye diseases
Do you wish to request the book?
Ocular RNA nanomedicine: engineered delivery nanoplatforms in treating eye diseases
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ocular RNA nanomedicine: engineered delivery nanoplatforms in treating eye diseases
2024
Overview
RNA therapy for eye diseases has good clinical translation potential, benefiting from the eye’s immune privilege, local drug delivery, and minimal dosage needs.RNA therapeutics play a crucial role in the treatment of genetic ocular diseases, which are directly linked to gene regulation.Delivering RNA to the eye’s posterior segment necessitates combination of delivery carriers and technology for effective in situ therapy.RNA nanomedicines have been utilized to reach specific targets in clinical treatments for eye diseases.Sequencing technology can deepen our understanding of eye diseases, revealing new diagnostic markers and therapeutic targets.
Ocular disorders remain a major global health challenge with unmet medical needs. RNA nanomedicine has shown significant therapeutic benefits and safety profiles in patients with complex eye disorders, already benefiting numerous patients with gene-related eye disorders. The effective delivery of RNA to the unique structure of the eye is challenging owing to RNA instability, off-target effects, and ocular physiological barriers. Specifically tailored RNA medication, coupled with sophisticated engineered delivery platforms, is crucial to guide and advance developments in treatments for oculopathy. Herein we review recent advances in RNA-based nanomedicine, innovative delivery strategies, and current clinical progress and present challenges in ocular disease therapy.
Ocular disorders remain a major global health challenge with unmet medical needs. RNA nanomedicine has shown significant therapeutic benefits and safety profiles in patients with complex eye disorders, already benefiting numerous patients with gene-related eye disorders. The effective delivery of RNA to the unique structure of the eye is challenging owing to RNA instability, off-target effects, and ocular physiological barriers. Specifically tailored RNA medication, coupled with sophisticated engineered delivery platforms, is crucial to guide and advance developments in treatments for oculopathy. Herein we review recent advances in RNA-based nanomedicine, innovative delivery strategies, and current clinical progress and present challenges in ocular disease therapy.
